Hound Partners, LLC Keros Therapeutics, Inc. Transaction History
Hound Partners, LLC
- $307 Million
- Q3 2024
Shares
2 transactions
Others Institutions Holding KROS
# of Institutions
174Shares Held
30.3MCall Options Held
76.8KPut Options Held
9K-
Black Rock Inc. New York, NY2.51MShares$141 Million0.0% of portfolio
-
Alkeon Capital Management LLC New York, NY1.9MShares$106 Million0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.86MShares$104 Million0.0% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y91.52MShares$85.2 Million7.2% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.51MShares$84.7 Million0.01% of portfolio
About Keros Therapeutics, Inc.
- Ticker KROS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,757,000
- Market Cap $1.44B
- Description
- Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...